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ORIGINAL RESEARCH ARTICLE
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Micheline Willea and Michiel Hemelsa
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Department of Pharmacy, University of Groningen, Groningen, the Netherlands; cMental Health and Public Health, University Paris-Sud,
Maison de Solenn, Paris, France; dCreativ-Ceutical, Paris, France; ePublic Health Department, Research Unit, Aix-Marseille University,
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ABSTRACT
Background and Objective: Orphan drugs have been a highlight of discussions due to
their higher prices than non-orphan drugs. There is currently no European consensus on the
method of value assessment for orphan drugs. This study assessed the relationship between
the prevalence of rare diseases and the annual treatment cost of orphan drugs in France,
Germany, Italy, Norway, Spain, Sweden, and UK.
Methods: Approved orphan drugs and prevalence data were extracted from the European
Medicines Agency website. Annual treatment costs were calculated using ex-factory price.
Simple regression was used to analyse the relationship between costs and prevalence. A
specific bivariate analysis was performed for the rarest diseases (≤1 per 10,000).
Results: 120 drugs were analysed. Prevalence ranged from 0.001 to 5 per 10,000 (mean 1.24,
median 1). Annual treatment costs per patient ranged from €755 to €1,051,956 (mean
€100,000, median €39,303). Results show a statistically significant inverse correlation
between annual treatment cost and disease prevalence in all countries (France: r = −0.370,
p = 0.002; Germany: r = −0.365, p = 0.002; Italy: r = −0.340, p = 0.002; Spain: r = −0.316,
p = 0.041; UK: r = −0.358, p = 0.0004; Sweden: r = −0.414, p = 0.014; Norway: r = −0.367,
p = 0.002). When analysis was focused on the rarest diseases, a stronger correlation exists in
all countries (France: r = −0.525, Germany: r = −0.482, Italy: r = −0.497, Spain: r = −0.531, UK:
r = −0.436, Sweden: r = −0.455, Norway: r = −0.466; all p < 0.05 except Sweden p = 0.077).
Conclusions: This study shows an inverse correlation between annual treatment cost and
prevalence with high statistical significance in the studied countries. Although pricing is a
complex process where different attributes are assessed, this study supports the idea that payers
value rarity in pricing decisions.
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Rare disease definition and burden
Rare diseases are uncommon and serious conditions
which are defined in the European Union (EU) as life-
threatening or chronically debilitating conditions with a
prevalence of no more than five in 10,000 people.[1] In
the UK, the National Institute of Health and Clinical
Excellence (NICE) in England and Wales has defined
ultra-rare diseases as diseases affecting less than 1000
patients in the UK.[2] Orphan drugs are medicines
intended for the diagnosis, prevention or treatment of
rare diseases.
Rare diseases are usually severe conditions with
no or limited choice of therapeutic options, and thus
present with a high level of unmet need. In 2007,
the EMA estimated that there are 5000 to 8000 rare
diseases affecting between 6% to 8% of the total EU
population, amounting to 27 million to 36 million
people in the EU.[1] The same report documented
that five new diseases are described in the medical
literature every week, hence current figures are
assumed to be higher. It is estimated that only 1%
are currently covered by approved treatments in the
EU.[3]
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Rare disease legislation and developments
Prior to 2000, commercial drug development in rare
diseases was prohibitive and limited. Due to the very
small number of patients affected, manufacturers
have been reluctant to invest in the research and
development (R&D) of orphan drugs as return on
investment is improbable. In 2000, EU legislation
141/2000,[4] also known as the European Orphan
Medicinal Products Regulation, has established a cen-
tralised procedure for the designation of orphan
medicinal products and has put in place regulatory
and economic incentives for the research, marketing,
and development of orphan drugs. It has allowed the
review and approval of orphan drugs, upholding the
principle of equity in patient access to treatment
which underpins the legislation.
The orphan drug legislation in Europe has been
considered a success since its enactment. As of July
2016 and more than 15 years after its inception, the
European Commission has designated 1329 products
as orphan medicinal products and has authorised
126 orphan medicines for the benefit of patients
suffering from rare diseases.[5] Orphan drug desig-
nation and marketing authorisation are two different
procedures set in continuum, both under the remit
of the European Medicines Agency (EMA). Although
an orphan designation may be granted once the
criteria of disease severity, low prevalence, and the
lack of satisfactory treatment options have been
fulfilled, marketing authorisation approval has regu-
latory requirements of safety and efficacy that must
be met. The incentives provided by the orphan drug
legislation aim to incentivise and support manufac-
turers through drug development and accelerate
regulatory assessment. However, many products
that are eligible for orphan designation may not be
commercially viable or may not be funded for devel-
opment. Some products are based on an off-patent
commercially available molecule and competition
with potential generics may prevent return on
investment. Some products may be based on a
patent-protected product and may need to wait for
the product to become off patent to initiate devel-
opment. Orphan designation is a relatively easy pro-
cess and does not require significant investment,
while drug development to achieve marketing
authorisation requires a very high investment, and
is very risky as success rates for development are
relatively low. Manufacturers may opt not go
through the marketing authorisation process if the
clinical proofs of concept are negative. Nonetheless,
the orphan drug legislation has seen an increase in
marketing authorisations in rare diseases. The EMA
has recommended the highest number of orphan
designated medicines for marketing authorisation
in a year in 2015: 18 approvals were intended for
rare disease compared to 40 approvals for non-
orphan new medicinal products. This is an increase
from the 17 orphan drug approvals in 2014, and the
11 drug approvals in 2013.[6]
The high costs of orphan drugs
The success which has resulted in an increasing number
of licensed medicines for rare diseases has also resulted
to a growing debate that relates to high costs and
affordability in the wake of the continuing economic
crisis and health budget austerity measures in Europe.
[7–14]
Orphan drugs have been a highlight of discussions
due to their higher price than non-orphan drugs. A
2011 budget impact study in 18 countries in Europe
[7] showed that the annual patient cost of commercially
available orphan drugs varied between €1,251 and
€407,631 with a median cost of €32,242 per treatment
year per patient. The share of the total pharmaceutical
market represented by orphan drugs was predicted to
peak from 3.3% in 2010 to 4.6% in 2016, and plateau at
4–5% until 2020, where absolute expenditure will
increase, but no faster than the growth of the greater
EU pharmaceutical market.[7]
Pricing of orphan drugs and surrounding issues
Price setting is a multifactorial decision with various
determinants such as R&D risk, return on investment,
unmet needs, availability of alternative therapies, the
drug’s additional value to current treatment options,
incremental cost effectiveness ratio, and pricing and
reimbursement (P&R) policies and processes. Although
orphan drugs are subjected to the usual pharmaceutical
drug pricing rationale in most countries, the European
legislation incentives have directly and indirectly influ-
enced the P&R landscape. In the literature, this has
been referred to as the ‘special market access status’
of orphan drugs.[11] Orphan drugs’ small target popu-
lation has resulted in a need for high prices, so that
manufacturers have the return on investment to cover
costs for drug development and post-marketing author-
isation surveillance. The high prices also create an
incentive for manufacturers to pursue investment in
the development of orphan drugs. As the costs and
margins have to be recovered from a limited number
of patients, this has led to high costs per patient.[12,15]
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Second, as they often are the only available treatment
option, some orphan drugs are considered to have high
value and thus benefit from high prices.[12] A study by
Picavet et al. [13] found that designated orphan drugs
achieve a higher median price than non-designated
orphan drugs that also target rare diseases (p < 0.01).
Third, 10 years of market exclusivity has led to mono-
polistic situations where manufacturers are in a position
of power to set prices.[8,11,12] Lastly, payers tend to
face pressure from patient groups regarding access to
medicines and thus comply to manufacturers’ price
demands as the rationale underpinning the EU legisla-
tion is equity in access to treatment.[12]
Price [8] and access of orphan drugs vary among
countries in the EU.[16–19] Although orphan designa-
tion and marketing authorisation is at a European level,
pricing and reimbursement are on a national level often
driven by health technology assessments (HTA)
outcomes and a variable impact from external reference
pricing.[20] In these HTAs, evidence requirements,
pricing and reimbursement decision frameworks, and
budget ceilings vary. Thus, prices and levels of access
vary.
National pricing regulations are often value-based
and the value placed on orphan drugs, as with any
intervention, varies per health care system. How much
they are willing to pay for a certain value is also a
relevant differentiator among countries. Some may
value equity where all patients deserve treatment and
put precedence on products that treat the greatest
health need, regardless of the high budget impact of
the orphan drug, while some may value maximising
health outcomes in the face of budget constraints.[18]
Often, it will be a combination of these arguments.
Other value drivers may include disease rarity, disease
severity, the availability of treatment options, the size of
clinical benefit, and incremental cost-effectiveness ratio.
Drug budget impact is rarely considered despite the
high per-patient price, due to low patient numbers in
rare diseases, and thus the drug budget impact is
usually low. In the UK, a societal preference survey [2]
done by NICE in 2004 showed that disease severity, the
size of the clinical benefit, and life threatening disease
may be valued in the NHS for orphan drug funding.
Disease rarity was not a reason found significant to pay
for price premium.[2] This matches well with the British
health technology evaluation culture which puts
efficiency first in economic evaluation by maximising
the total health gain through cost per quality-adjusted
life years (QALY) computations. QALY, the measure of
health gain, is the outcome used to assess the appro-
priate use of limited health care resources. The UK
seems to consider a QALY is a QALY, regardless of
who gains or loses it, and the willingness to pay is not
driven by rarity.[21] Exceptions however exist for end-
of-life treatments with QALYs reflecting quantitative
assessment and rarity and equity considered from a
qualitative and societal point of view.
It has been questioned whether the current value
assessment frameworks truly reflect social preferences
and values in terms of funding orphan drugs.[21] The
UK study described above showed no explicit societal
values prioritising rarity.[2] In a Norwegian survey of
1479 people, 80% answered that rare diseases should
have the same equal access to health care regardless of
costs but only 42% were willing to equally divide health
care funds between rare and common diseases.[22]
Although most studies such as these are small and
have been suggested to have methodological flaws
and thus should be interpreted with caution,
Drummond et al. [9] have discussed that these
conflicting findings may be explained by two notions
of equity: horizontal equity versus vertical equity.
Horizontal equity is defined as the equal treatment of
equals.[9] On the other hand, vertical equity is the
unequal but equitable treatment of unequals.[9,21] A
health care system which uses a single cost per QALY
threshold for all reflects horizontal equity. A health care
system which regards the unique state of patients with
rare diseases and that these patients are equally
entitled to treatment even if it means foregoing
efficiency standards reflects vertical equity. As to
which should be prioritised is still an ongoing
discussion and the answer may differ per institution.[9]
As a fair amount of literature has argued on how
orphan drugs should be treated in terms of pricing and
market access,[8,9,11,23] collaborations have been
proposed to better understand the value of orphan
drugs in light of P&R decisions.[21] As the usual HTA
frameworks have been criticised to be limited for the
complete evaluation of orphan drugs,[9,15,24] multiple
criteria decision analysis (MCDA) frameworks which
incorporate relevant value elements into P&R decision
in a transparent and consistent matter [25–28] and
other price control mechanisms such as cost-plus or
rate of return models employing yardsticked cost
allocations and rate of return calculations in setting
orphan drug prices [29] have been proposed.
Significance and objective of the study
Studies on how orphan drugs are priced in Europe are
sparse and the pricing of these drugs has been referred
to as a black box.[12,14] There is currently no European
consensus on how the value of orphan drugs are and
should be assessed.[24]
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With the ongoing discussion on should we value
rarity and on how European health care systems should
assess and price orphan drugs, understanding the value
drivers that payers attach to orphan drugs is important.
Studies focusing on evaluating the present system will
pave the way to new pricing and reimbursement
strategies.
As prevalence is the cornerstone of orphan drug
designation, do payers value rarity in pricing decisions?
Do payers seem to accept higher prices for orphan
drugs, as initially priced by manufacturers? The
objective of this study is to assess the relationship
between the annual cost of treatment per patient of
orphan drugs (price) and the prevalence (rarity) of the
corresponding rare diseases in Europe.
Methodology
A five-step process was implemented in order to
assess the relationship between the annual cost of
treatment of orphan drugs and the prevalence of the
corresponding rare diseases: (1) extraction of the
approved orphan drugs from the European Medicines
Agency (EMA) website; (2) extraction of ex-factory
price for all products in the countries of scope from
IHS POLI database and country-specific price database;
(3) calculation of annual treatment cost per patient; (4)
extraction of disease prevalence at EU level from the
EMA website; and (5) analysis of annual treatment
costs versus disease prevalence. The countries
included were France, Germany, Italy, Norway, Spain,
Sweden and the UK.
Extraction of orphan drugs from EMA website
We searched the EMA database for the list of approved
orphan drugs and their approved indications. Orphan
drugs granted marketing authorisation up to 13 June
2016 including drugs with expired or withdrawn
orphan drug designations were extracted for analysis.
Only one indication per orphan drug was used in the
analysis. If the orphan drug was approved for more
than one indication, the first EMA indication approved
was chosen for inclusion in the analysis. If both indica-
tions were approved at the same time, the least pre-
valent indication was chosen for inclusion.
Extraction of ex-factory price from IHS POLI
database and country-specific price database
The IHS POLI database [30] was the primary source of
price data. For drugs with withdrawn and expired
orphan designations with no available prices in POLI,
available country-specific price databases were used:
Database of drugs and tariffs (Ameli) [31] for France,
British National Formulary (BNF) [32] for the UK, and
Farmadati Compendio Farmaceutico Telematico
database [33] for Italy.
The earliest price was used for cost calculation as we
are interested in the prices at launch and drug prices
change over time. An exception to this was when using
BNF, where current prices were extracted because price
history was not available.
Prices in British pound sterling, Swedish krona, and
Norwegian krone, were converted to Euros by applying
the respective exchange rates: €1 = £0.72, €1 = 9.09
Swedish Krona, €1 = 9.09 Norwegian Krone. Conversion
was done by the IHS database system upon extraction
and the same conversion rates were used for BNF prices.
Calculation of annual treatment cost per patient
We calculated the annual treatment cost per patient in
each country for each orphan drug based on the annual
treatment dose according to the standard treatment
plan described in the Summary of Product
Characteristics (SmPC). Across all seven countries, the
indication and posology are the same. There are
differences in the preparation and formulation of
drugs across countries but these are minor. As much
as possible, the same formulation and preparation per
product were used in all countries for ease of
comparability.
Assumptions were used during dose and cost
computations as dosing of orphan drug treatments
may vary according to patient age, weight, disease
severity, patient needs, disease progression, or disease
complications.
● Average drug dose for an adult was used unless
the drug would be specifically indicated for use in
children. For drugs indicated for both adults and
paediatric populations, the pivotal studies
described in the European Public Assessment
Report (EPAR) were consulted for the average
age range of the population included in clinical
trials and dosage and cost computation were
done for this specific average patient. For weight
adjusted and body surface area (BSA) adjusted
treatments, the average weight of an adult is set
at 70 kg and the average body surface area is set
at 1.73 m2. Standard average values for other age
intervals were also used.[34]
● If the dose is adjustable based on performance
results or an average dose was given, information
regarding the average treatment duration and
4 G. MEDIC AL.
dosage from the EPAR and pivotal studies were
used. In the same manner, for cycle-based
treatments where the number of cycles varies,
the mean number of cycles in the pivotal trials
was assumed.
● Treatment duration of 365 days was assumed. For
drugs used for less than a year, the costs of the
total treatment course were analysed as annual
costs.
● For treatments administered as injection or
infusion, the nearest full vial size was used.
The EPAR was consulted if vials can be stored
once opened or should be used within the day.
Vial wastage in this sense was taken into
consideration.
● If there was an unfinished pack at the end of
the year or at the end of a treatment cycle, only
a proportion of the price of that pack was
accounted for.
Extraction of disease prevalence at EU level from
the EMA website
The prevalence of rare diseases reported in the EMA
website [35] were used for analysis. The reported
prevalence rates were at the EU level thus the
same rare disease prevalence was used for all coun-
try analysis. If the prevalence was reported as a
range, the average prevalence was used. If the pre-
valence was indicated as less than a certain number,
the nearest number less than the indicated number
was used (e.g. less than 0.2 per 10,000 is 0.19).
Analysis of annual treatment costs versus disease
prevalence
Straightforward linear regression analysis was done
and correlation coefficients were computed to deter-
mine the relationship between the annual treatment
cost and prevalence of rare diseases per country.
Results were plotted per country. A significant num-
ber of orphan drugs were for the rarest diseases
(prevalence 0–1 per 10,000) and a specific bivariate
analysis between annual costs and prevalence was
performed for this very low-prevalence cohort. A spe-
cific linear regression was also done for France refer-
encing the ASMR (Amélioration du Service Médical
Rendu) scores for each orphan drug from the health
technology assessments (HTA) done by Haute
Autorité de Santé (HAS). ASMR is a driver of price
setting in France. Thus, the sub-analysis assessed
the relationship between disease prevalence and
ASMR, and ASMR and annual treatment costs.
Results
Ninety-five authorised orphan drugs were extracted
from the EMA website and were complemented with
25 drugs with expired or withdrawn orphan drug
designations, for a total of 120 (Table 1). The pre-
valence ranged from 0.001 to 5 patients per 10,000
with a mean of 1.24 per 10,000 and a median of 1
per 10,000.
Not all orphan drugs are commercially available in
all seven countries and not all commercially avail-
able orphan drugs had available prices for analysis.
For example, in many countries, drugs for hospital
use do not have listed prices. The prices for these
drugs are negotiated on a case by case basis with
each hospital and are confidential. The number of
drugs analysed per country is presented in Table 2.
In all seven countries, the annual treatment costs
per patient ranged from €755 to €1,051,956 with a
mean of €100,000 and median of €39,303. Country
differences in annual treatment costs are shown in
Figure 1. Germany had the highest mean annual
treatment cost, followed by Norway, France, UK,
Italy, Spain, and Sweden, respectively.
In all the countries, results showed an inverse corre-
lation between disease prevalence and annual treat-
ment cost with the rarer the disease, the more
expensive the treatment (FR: r = −0.370, p = 0.002; DE:
r = −0.365, p = 0.002; IT: r = −0.340, p = 0.002; ES:
r = −0.316, p = 0.041; UK: r = −0.358, p = 0.0004; SE:
r = −0.414, p = 0.014; NO: r = −0.367, p = 0.002). Very
high statistical significance was met in all countries.
Of the drugs, 53% were in the very low prevalence
cohort (prevalence 0–1 per 10,000) and when analysis
was focused on these rarest diseases, a stronger
correlation was found in all countries (FR: r = −0.525,
p = 0.001; DE: r = −0.482, p = 0.003; IT: r = −0.497,
p = 0.001; ES: r = −0.531, p = 0.019; UK: r = −0.436,
p = 0.001; SE: r = −0.455, p = 0.077; NO: r = −0.466,
p = 0.004; all p < 0.05 except SE) (Figures 2–15).
When we modelled the data where the logarithm of
the prevalence was used as the exogenous variable, it
showed an inverse linear relationship between prevalence
and cost. Figures are presented in the supplementary file.
The sub analysis in France showed a statistically sig-
nificant direct correlation between prevalence and ASMR,
with a lower ASMR score (higher additional benefit) given
the rarer the disease (r = 0.257, p < 0.05). It also showed a
statistically significant inverse correlation between ASMR
and the annual treatment costs, with the treatment with
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Adcetris Hodgkin disease 1.00
Adempas Pulmonary hypertension 2.00
Afinitor* Renal cell carcinoma 4.20
Aldurazyme* Mucopolysaccharidosis I 0.03
Alprolix** Haemophilia B 0.20
Arzerra Chronic lymphocytic leukaemia 3.50
Atriance Precursor T-Cell lymphoblastic leukaemia-lymphoma 1.10
Blincyto Precursor cell lymphoblastic leukaemia-lymphoma 1.00
Bosulif Chronic myeloid leukaemia 1.60
Bronchitol Cystic fibrosis 1.30
Busilvex* Conditioning treatment prior to haematopoietic-progenitor-cell transplantation 0.70
Carbaglu N-acetylglutamate synthetase deficiency 0.00
Cayston Gram negative bacterial lung infection in cystic fibrosis 1.30
Ceplene Acute myeloid leukaemia 0.70
Cerdelga Gaucher disease type 1 0.30
Coagadex** Hereditary factor X deficiency 0.09
Cometriq Metastatic medullary thyroid carcinoma 0.70
Cresemba Mucormycosis 0.06
Cyramza* Stomach neoplasms (Gastric cancer) 3.00
Cystadane Homocystinuria 0.17
Dacogen Acute myeloid leukaemia 1.00
Darzalex** Plasma cell myeloma 1.75
Defitelio** Severe hepatic veno-occlusive disease 0.40
Deltyba Tuberculosis 2.00
Diacomit Severe myoclonic epilepsy in infancy 0.40
Elaprase Mucopolysaccharidosis II 0.02
Esbriet Idiopathic pulmonary fibrosis 3.00
Evoltra Precursor cell lymphoblastic leukaemia-lymphoma 0.40
Exjade Iron overload 2.70
Fabrazyme* Fabry disease 0.03
Farydak Multiple myeloma 3.20
Firazyr Hereditary angioedemas 2.50
Firdapse Lambert-Eaton myasthenic syndrome 0.10
Galafold** Fabry disease 1.00
Gazyvaro Chronic lymphocytic leukaemia (follicular lymphoma) 2.40
Gliolan Malignant glioma 3.70
Glivec* Chronic myeloid leukaemia 0.90
Glybera Familial lipoprotein lipase deficiency 0.02
Granupas Tuberculosis 2.00
Hetlioz** Non-24-hour sleep-wake disorder 1.85
Holoclar** Limbal stem cell deficiency 0.30
Iclusig Chronic myeloid leukaemia 0.80
Idelvion Haemophilia B 0.10
Ilaris* Cryopirin associated syndromes 0.05
Imbruvica Mantle cell lymphoma 0.17
Imnovid Multiple myeloma 2.20
Increlex Laron syndrome 2.00
Inovelon Epilepsy 1.50
Jakavi* Chronic idiopathic myelofibrosis 0.50
Kalydeco Cystic fibrosis 1.20
Kanuma Lysosomal acid lipase deficiency 0.20
Ketoconazole
HRA
Endogenous Cushing’s syndrome 0.90
Kolbam Inborn errors in primary bile acid synthesis 0.07
Kuvan Phenylketonurias 1.70
Kyprolis Multiple myeloma 1.30
Lenvima Differentiated thyroid carcinoma 0.60
Litak* Hairy cell leukaemia 2.40
Lynparza Ovarian cancer 2.90
Lysodren* Adrenal cortex neoplasms 0.10
Mepact Osteosarcoma 0.50
Mozobil Hematopoietic stem cell transplantation for multiple myeloma, lymphoma 1.00
Myozyme Glycogen storage disease type II 0.14
Naglazyme* Mucopolysaccharidosis VI 0.02
Nexavar Renal cell carcinoma 3.01
Nexobrid Deep partial- and full-thickness thermal burns 1.00
Nplate Thrombocytopenic idiopathic purpura 1.00
Ofev Idiopathic pulmonary fibrosis 3.00
Opsumit Pulmonary arterial hypertension 1.80
Orfadin* Tyrosinemias 0.10
(Continued )
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the lower ASMR score (higher additional benefit) being
more expensive (r = −0.265, p < 0.05).
Discussion
Publications related to predictors of price in rare dis-
eases, specifically with rarity as an explanatory variable,
are few (Table 3). Most of these studies are not com-
prehensive in terms of the number of orphan drugs
analysed and the number of European countries
scoped. These studies were also performed when
fewer orphan drugs were launched. To our knowledge
this work is the most comprehensive research assessing





Orphacol Digestive system diseases, inborn errors of metabolism 0.06
Pedea* Patent ductus arteriosus 2.13
Peyona Primary apnoea 0.85
Photobarr* Barrett oesophagus 3.60
Plenadren Adrenal insufficiency 4.50
Prialt* Pain injections, spinal 1.54
Procysbi Nephropathic cystinosis 0.10
Raxone Leber’s hereditary optic neuropathy 1.00
Ravicti** Carbamoyl-phosphate synthase-1 deficiency 0.14
Replagal* Fabry disease 0.02
Revatio* Pulmonary hypertension 1.00
Revestive Short-bowel syndrome 0.20
Revlimid Multiple myeloma 1.30
Revolade* Idiopathic thrombocytopenic purpura 2.50
Savene Extravasation of diagnostic and therapeutic materials 0.03
Scenesse** Erythropoietic protoporphyria 0.19
Signifor Cushing’s disease 1.20
Siklos Sickle cell anaemia 0.50
Sirturo Pulmonary multidrug resistant tuberculosis 2.00
Soliris Paroxysmal nocturnal haemoglobinuria 0.10
Somavert Acromegaly 0.60
Sprycel Chronic myelogenous leukaemia, BCR-ABL positive 0.89
Strensiq Hypophosphatasia 0.10
Strimvelis Adenosine deaminase deficiency 0.02
Sutent* Malignant gastrointestinal stromal tumours 0.30
Sylvant Multicentric Castlemans disease who are human immunodeficiency virus (HIV) negative and human herpesvirus-8
(HHV-8) negative
0.99
Tasigna Chronic myelogenous leukaemia, BCR-ABL positive 1.00






Thelin Pulmonary arterial hypertension 0.50
Tobi Podhaler Pseudomonas aeruginosa lung infection in cystic fibrosis 1.30
Torisel Renal cell carcinoma 3.50
Tracleer* Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension 0.95
Translarna** Duchenne muscular dystrophy 0.30
Trisenox* Acute promyelocytic leukaemia 0.80
Unituxin** Neuroblastoma 1.10
Uptravi Pulmonary arterial hypertension 1.80
Ventavis* Primary pulmonary hypertension 2.20
Vidaza Myelodysplastic syndromes 2.05
Vimizim Mucopolysaccharidosis, type IVA (Morquio A syndrome) 1.40
Volibris Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension 2.00
Votubia Renal angiomyolipoma with tuberous sclerosis complex 1.00
VPRIV Gaucher disease 0.30
Vyndaqel Transthyretin amyloidosis 2.90
Wakix** Narcolepsy 5.00
Wilzin* Hepatolenticular degeneration 0.60
Xagrid Essential thrombocythaemia 2.50
Xaluprine Acute lymphoblastic leukaemia 1.20
Xyrem* Narcolepsy 5.00
Yondelis Sarcoma 0.61
Zavesca Gaucher disease 0.60
*Orphan designation withdrawn or expired.
** No prices available in the countries in scope; probably not commercially available.
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This study shows a significant inverse relationship
between orphan drug annual treatment cost and dis-
ease prevalence in Europe. Although sample size was
not that large and despite price being a multifactorial
outcome, statistical significance was met in all coun-
tries. These results are aligned with the results of all the
previous studies presented in Table 3.[14,36–39]
The number of drugs analysed per country varied,
with Sweden (N = 35) and Spain (N = 42) having the
least drugs analysed due to the lower number of
orphan drugs with publicly available prices. The low
sample size in Sweden probably explains why the
inverse correlation between annual costs and the rar-
est diseases prevalence (prevalence of 0–1 per 10,000)
did not meet statistical significance. Only 16 drugs out
of the 35 were analysed, compared to 19 to 52 drugs
in the other countries when considering the lowest
prevalence disorders.
Annual treatment costs were used to compare
prices because it is not possible to compare prices
directly from the database as it only provides prices
per available pack, and thus adjustments to annual
treatment prices had to be performed for the purpose
of this analysis. The comparison of annual treatment
costs of orphan drugs among countries shows that
the costs of drugs in northern European countries are
higher than in southern Europe. Sweden was again an
outlier probably due the smaller sample size. Annual
treatment costs ranges from as low as less than
€1,000 to more than €1,000,000. This is a wide range
considering that all of these drugs are designated to
rare, life-threatening or chronically debilitating condi-
tions. The cost range is the same for the rarest disease
cohort (prevalence of 0–1 per 10,000). The drug with
the lowest annual cost is Onsenal (celecoxib) for the
treatment of familial adenomatous polyposis (FAP)
with a disease prevalence of 0.3 per 10,000. Onsenal
has an annual treatment cost per patient of €755 in
Italy. It has however been withdrawn from the market
by EMA post-approval at the request of the marketing
authorisation holder (MAH) due to MAH’s inability to
provide the additional data required, as a result of
slow enrolment in an ongoing clinical trial.[40] The
drug with the highest annual cost is Glybera (alipo-
gene tiparvovec) for the treatment of familial lipopro-
tein lipase deficiency (LPLD) which has a prevalence
Table 2. Number of orphan drugs analysed per country.
Country
Number of orphan drugs with
prevalence of 0–5 per 10,000
Number of orphan drugs









Figure 1. Orphan drugs annual treatment costs in seven EU countries.
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of 0.02 per 10,000. It is the first gene therapy drug
that has been approved by the EMA and is currently
only available in Germany at a launch annual treat-
ment cost of €1,051,956 per patient. In between these
two extreme annual costs, the data range shows an
inverse relationship between cost and rarity.
Pricing of orphan drugs is a complex process with
multiple price determinants. Two recent studies looked
into the decision drivers of orphan drugs price setting
in Europe and both supported the general notion that
orphan drug pricing in Europe is inconsistent and non-
transparent. Onakpoya et al. [39] in 2014 showed that
the annual cost of drugs in the UK did not appear to be
related to their clinical effectiveness and that there is no
clear and standardised mechanism for determining
their prices. The difficulties in generating evidence for
rare diseases and the lack of robust information when
the price is set are probable factors. Picavet et al. [14] in
2014, through a multiple regression analysis, showed
that prices of orphan drugs in six EU countries are
influenced by factors such as the availability of an
alternative drug treatment, repurposing of the drug,
the length of treatment, the administration route, the
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Germany Annual Treatment Cost Per Prevalence (0-5 per 10,000)
Figure 4. Germany annual treatment cost per prevalence (0–5 per 10,000).
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overall survival and quality of life (QoL). The study
however indicates that relevant vagueness still sur-
rounds the orphan drug pricing mechanism.
In most countries, severity of disease has an impact
on P&R decisions in Europe. This was exemplified by the
NICE Citizen’s Council Report.[2] No studies were found
analysing the correlation of rare disease severity to
price. A reason for this is that there is no reliable data
available for rare diseases on disease severity that can
be used in a regression analysis.[14] It is worthwhile to
investigate if disease rarity contributes to disease sever-
ity perception in payer value assessments. If rarity is
found to contribute to severity and payers value sever-
ity, it can be deduced that payers value rarity. The sub
analysis in France assessed the relationship between
disease rarity and severity in payer assessments. The
French P&R system uses two scores to assess a drug’s
value: the Service Médical Rendu (SMR), also called the
Actual Benefit (AB), and the Amélioration du Service
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Figure 7. Italy annual treatment cost per prevalence (0–1 per 10,000).
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Actual Benefit (IAB). SMR is the driver of reimbursement
decision and an insufficient SMR leads to non-reimbur-
sement. SMR is based on several criteria such as disease
severity, treatment efficacy and safety, the type of treat-
ment (preventive, curative or symptomatic), its position
in the therapeutic strategy, the presence of alternative
treatment options and its impact on public health.[41]
Severity being one of the criteria shows that payers in
France value severity. On the other hand, ASMR is the
driver for price determination and reflects drug efficacy
compared to existing treatments.[41] ASMR has five
levels ranging from one to five (I to V). A score of I
signifies major improvement or a therapeutic break-
through and a score of V signifies no clinical improve-
ment. ASMR from I to III leads to a price premium. Our
sub analysis showed a statistically significant direct cor-
relation between prevalence and ASMR, where a lower
ASMR score was given the rarer the disease. It also
showed a significant inverse correlation between
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Spain Annual Treatment cost per Prevalence (0-5 per 10,000)
Figure 10. Spain annual treatment cost per prevalence (0–5 per 10,000).
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costs were observed with lower ASMR scores. This sub
analysis strengthens the results of our study that payers
in France value rarity and is reflected in the lower ASMR
scores and higher price premiums for rarer diseases.
Payers in France also value severity through positive
reimbursement decisions. Although this sub analysis
has not shown that disease rarity contributes to disease
severity, which in turn leads to a higher price due to the
specificities in the French system, where disease sever-
ity is a driver of reimbursement and not price, this may
still be a probable scenario in other countries with
different P&R systems. At the same time, almost all
orphan drugs were assessed with high SMR scores
unlike non-rare conditions.
In the UK, the Citizen’s Council report [2] showed that
willingness to pay is not driven by rarity and NICE HTA has
been known to uphold cost per QALY benchmarks as the
norm. However, our results showed otherwise and that
payers in the UK valued rarity. A comprehensive study on
the use of incremental cost per QALY gained in ultra-rare
disorder by Schlander et al. [21] discussed that a growing
body of literature considers cost per QALY economic eva-
luations in ultra-rare diseases as flawed, raising concerns on
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Sweden Annual Treatment cost per Prevalence (0-1 per 10,000)
Figure 13. Sweden annual treatment cost per prevalence (0–1 per 10,000).
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standard cost per QALY benchmarks. The study argued that
these traditional HTAs are an oversimplification of the com-
plexities of health care priority setting and decisionmaking,
and that social values cannot be simply associated with
decreasing incremental cost-effectiveness ratios (ICERs).
The same study discussed that the introduction of the
‘ultra-orphan’ category by NICE as well as another category
called ‘end-of-life treatments’ can be interpreted to be
made in response to public pressure on NICE with regards
to discussions around horizontal equity versus vertical
equity, and the need for an evaluation framework which
reflects social preferences while remaining consistent to
normative commitments but addresses the limitation of
the logic that all QALYs are created equal.[21] This can be
interpreted that a differential cost per QALY benchmark
may have been considered in the UK, valuing rarity in the
evaluation of ultra-rare diseases. Therefore, one may con-
sider that the NICE and SMC decision frameworks which
favour horizontal equity through a predefined cost per
QALY do not apply to orphan drugs in actuality. Ultra-rare
diseases operate through a process that favours vertical
equity. The ambiguity highlights the complexity in operat-
ing through a single framework for both rare and more
common diseases.
All countries that opt for vertical equity, such as
Germany, France and Sweden, as well as countries
that opt for horizontal equity, such as the UK, value
rarity in practice and tend to pay higher prices for the
lowest prevalence. While this is consistent for the
former group, it comes as a surprise for the latter.
Our methodology and results are in line with a previous
study by Picavet et al. [14] which showed that orphan drug
prices are determined based on the prevalence of the first
indication. Launch prices for the first indication are unlikely
to be reviewed following approval and combined preva-
lence is not a determinant for price setting, thus multiple
indications for an orphan drug are associated with higher
prices.[14]
Although drug price is amultivariate decision, this study
answers the question: do payers value rarity? Payers in
Europe do although it is not the sole criteria on which
drug pricing is based on. The weight of the value given to
rarity varies per health care system as well. This study sheds
someunderstanding on the value drivers that payers attach
to orphan drugs in light of the ongoing discussion of
whether rarity should be valued and how European health
care systems should assess and price orphan drugs. This
studyprovides robust evidence that payers value raritywith
a high correlation and that the correlation increases when
tested on themost rare disease segment (prevalence of 0–1
per 10,000). Assessment of value of orphan drugs considers
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Figure 15. UK annual treatment cost per prevalence (0–1 per 10,000).
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need, clinical benefit and budget impact. The rarity of a
disease does onlyminimally affect the cost of development
and therefore rarity inevitably leads to a notably higher
price point. A sustainable price level is essential in ensuring
long term innovation for patients with rare diseases.
Limitations of this research
The prevalence data at the EU level may not accurately
represent the actual rate in the countries analysed. Rare
disease prevalence often represents the number of clini-
cally diagnosed patients, but more patients may be
exposed to the disease. Another point to consider is that
only a percentage of these patients may have clinically
significant disease which warrants treatment, and not all
patients are treated. However, although differences in pre-
valence may exist, these are expected to be infrequent
phenomena.
In terms of treatment indications, only one indication
per orphan drug was included in the analysis. This may
have skewed the correlation as treatment costs of the
other approved indications were not included. However,
the first EMA-approved indications were chosen and the
earliest prices were taken into account in the analysis
and thus reflected pricing decisions upon launch.
Lastly, the prices of the drugs are listed prices
which are often not aligned with the actual net prices,
the latter being a better reflection of health care
expenditures on orphan drugs. Confidential discounts,
rebates, and tenders may be negotiated at the
national, regional, or provider level, which may distort
the ex-factory price. However, the potential discounts
and rebates are expected to be reasonably homoge-
neous for all orphan drugs within the same country
and prevalence will unlikely drive rebates or discounts
during negotiations.
Conclusion
In all the countries in scope, this study shows an inverse
correlation between annual treatment cost and disease
prevalence with high statistical significance. Although pri-
cing is a complex process where different attributes are
assessed, this study suggests that payers in all the coun-
tries value rarity of disease in pricing decisions. This ana-
lysis generated robust results which can support the
continuous discussion on the development of more con-
sistent and transparent value assessments of orphan
drugs in Europe.
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